Home/Pipeline/LBP for IPF

LBP for IPF

Idiopathic Pulmonary Fibrosis (IPF)

PreclinicalActive

Key Facts

Indication

Idiopathic Pulmonary Fibrosis (IPF)

Phase

Preclinical

Status

Active

Company

Alveolus Bio

About Alveolus Bio

Alveolus Bio is an early-stage biotech developing first-in-class inhaled live biotherapeutics for chronic respiratory diseases. The company's core innovation is the resMIT platform, designed for targeted pulmonary delivery of bacteria to modulate the lung microbiome and treat underlying disease mechanisms like fibroblast dysfunction and inflammation. With a strong, interdisciplinary team and a preclinical pipeline targeting high-need indications such as IPF and COPD, Alveolus Bio is positioned to pursue a novel therapeutic approach in a field dominated by small molecules and biologics. The company is privately held, pre-revenue, and actively seeking investment and partnerships to advance its programs.

View full company profile

Therapeutic Areas

Respiratory Diseases Idiopathic Pulmonary Fibrosis COPD Bronchiectasis

Other Idiopathic Pulmonary Fibrosis (IPF) Drugs

Drug	Company	Phase	Status
OATD-01	Molecure	Phase II	Active, recruiting
FP-020 (BMS-986235)	Foresee Pharmaceuticals	Phase 2	Active
Buloxibutid (C21)	Vicore Pharma	Phase 2b	Active, Now Enrolling
AP02	Avalyn Pharmaceuticals	Phase 2	Active
Gento-Fibrose Pulmonaire Program	Genoscience Pharma	Preclinical	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
NLM-001	Nelum Pharma	Phase 1	Active
GNS-3545 (ROCK2 Inhibitor)	Genosco	Phase 1	Active
TG2 Inhibitor Program	Isterian Biotech	Preclinical	Active
Taladegib (ENV-101)	Endeavor BioMedicines	Phase 2b	Active
CAL101	Calluna Pharma	Phase 2	Active
NVP-13	Velvio	Pre-clinical	Active